Back to Search
Start Over
Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
- Source :
-
International journal of antimicrobial agents [Int J Antimicrob Agents] 2024 Jun; Vol. 63 (6), pp. 107165. Date of Electronic Publication: 2024 Apr 01. - Publication Year :
- 2024
-
Abstract
- Background: Oritavancin and dalbavancin are long-acting lipoglycopeptide antibiotics approved for the treatment of skin and skin structure infections. Recently, they have been used for outpatient antimicrobial therapy for complicated infections. No head-to-head studies exist for this purpose.<br />Objective: To compare outcomes of patients treated with multiple doses of oritavancin or dalbavancin for complicated infections.<br />Patients and Methods: This was a single-centre, retrospective cohort study evaluating adult patients who received two or more doses of lipoglycopeptides for complicated infections from February 2019 through December 2022. Patients receiving oritavancin were compared to dalbavancin after propensity score-matching. The primary endpoint was clinical success at 90 days. Other endpoints included: 30-day re-admission, 30-day mortality, adverse drug reactions (ADRs), and changes in white blood cell count and inflammatory markers after the first dose.<br />Results: After exclusions and propensity score-matching, 131 matched pairs (N = 262) were included in the analysis. Most patients were receiving lipoglycopeptide therapy for osteomyelitis. There was no significant difference in clinical success at 90 days in patients who received oritavancin compared to those who received dalbavancin (99 [76%] vs. 103 [79%], respectively; P = 0.556). There was no significant difference in secondary endpoints, however, there was a trend towards higher incidence of ADRs oritavancin compared to dalbavancin (9 [7%] vs. 2 [2%], respectively; P = 0.060) which led to more treatment discontinuation.<br />Conclusion: There was no significant difference in efficacy between multi-dose oritavancin and dalbavancin for the treatment of complicated infections. Both agents were generally well tolerated; however, dalbavancin may be better tolerated when long-term treatment is warranted.<br /> (Copyright © 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)
- Subjects :
- Humans
Male
Female
Retrospective Studies
Middle Aged
Aged
Adult
Treatment Outcome
Osteomyelitis drug therapy
Aged, 80 and over
Vancomycin analogs & derivatives
Teicoplanin analogs & derivatives
Teicoplanin therapeutic use
Teicoplanin adverse effects
Teicoplanin administration & dosage
Propensity Score
Anti-Bacterial Agents therapeutic use
Anti-Bacterial Agents adverse effects
Anti-Bacterial Agents administration & dosage
Lipoglycopeptides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1872-7913
- Volume :
- 63
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- International journal of antimicrobial agents
- Publication Type :
- Academic Journal
- Accession number :
- 38570019
- Full Text :
- https://doi.org/10.1016/j.ijantimicag.2024.107165